1 month Arcus Biosciences (NYSE:RCUS) Receives New Coverage from Analysts at HC WainwrightMarketBeat
HC Wainwright started coverage on shares of Arcus Biosciences in a research report on Monday. They set a “neutral” rating and a $20.00 price objective for the company.
X